Clinical trial
Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in…
NCT00221650 · University Hospital, Bordeaux, Other · Completed
Key facts
| NCT number | NCT00221650 |
|---|---|
| Title | Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-Infected Patients |
| Official title | Efficacy and Safety of Peginterferon alfa2a and Ribavirin for the Second Line Treatment of Chronic Hepatitis C in HIV Infected Patients Previously Non Responders to a First Anti-HCV Treatment |
| Acronym | ROCO2 |
| Lead sponsor | University Hospital, Bordeaux, Other |
| Collaborators | Hoffmann-La Roche Industry Ministry of Health, France |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections, Hepatitis C, Chronic, Treatment Failure |
| Intervention type | Drug |
| Interventions | Peginterferon alfa2a, Ribavirin |
| Enrollment | 17 |
| Start date | Apr 1, 2002 |
| Completion | Jun 1, 2004 |
| First posted | Sep 22, 2005 |
| Last update posted | Jun 13, 2007 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: